Lumida
/NVAX
⌘K
Novavax Inc

Novavax Inc

NVAX
$9.42USD+1.29%+0.12 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $10

52W RANGE

$6
$12

AI Summary

Stalk
StalkMedium

NVAX is consolidating in a neutral to cautious phase within its Stage 2 uptrend, trading between the 9- and 20-day EMAs after a pullback from early-September highs. The long-term trend remains up above the 50- and 200-day SMAs, but short-term momentum has cooled with RSI near 58 and moderate Options Score. Under a speculative strategy, execution favors deferred entries on pullback acceptance into the EMA support zone, avoiding premature buys until clear support is confirmed.

  • Sanofi partnership expands licensed reach toward a $100B-plus vaccine market
  • Q2 product sales up 76% YoY to $19M, driven by Matrix-M adjuvant
  • Q2 revenue plunged to $57M from $239M YoY, showing high fluctuation
Full analysis →
Insider Trades40 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Mar 7, 2026SellNVAXJames Patrick KellyEVP, CFO and Treasurer5,904$9.98$1.6B-21.30%+51.94%$58.9K-4.33%Trim
Mar 3, 2026SellNVAXRuxandra Draghia-AkliEVP, Research & Development11,313$9.49$1.6B-21.30%+51.94%$107.4K-3.44%Trim
Mar 3, 2026SellNVAXMark J CaseyEVP, Chief Legal Officer11,378$9.49$1.6B-21.30%+51.94%$108.0K-10.79%Trim
Mar 3, 2026SellNVAXJames Patrick KellyEVP, CFO and Treasurer20,850$9.49$1.6B-21.30%+51.94%$197.9K-9.01%Trim
Mar 3, 2026SellNVAXElaine O'HaraEVP, Chief Strategy Officer22,429$9.49$1.6B-21.30%+51.94%$212.9K-8.32%Trim
Mar 3, 2026SellNVAXJohn C JacobsPresident and CEO69,288$9.49$1.6B-21.30%+51.94%$657.5K-11.64%Trim
Mar 1, 2026SellNVAXMark J CaseyEVP, Chief Legal Officer1,214$10.14$1.6B-21.30%+51.94%$12.3K-0.38%Trim
Mar 1, 2026SellNVAXElaine O'HaraEVP, Chief Strategy Officer16,344$10.14$1.6B-21.30%+51.94%$165.7K-3.12%Trim
Mar 1, 2026SellNVAXJames Patrick KellyEVP, CFO and Treasurer28,366$10.14$1.6B-21.30%+51.94%$287.6K-5.53%Trim
Mar 1, 2026SellNVAXJohn C JacobsPresident and CEO38,450$10.14$1.6B-21.30%+51.94%$389.9K-3.25%Trim
Jan 23, 2026SellNVAXJohn C JacobsPresident and CEO39,132$9.17$1.6B-21.30%+51.94%$358.8K-17.79%Trim
Dec 11, 2025SellNVAXMark J CaseyEVP, Chief Legal Officer12,713$6.69$1.6B-21.30%+51.94%$85.0K-10.98%Trim
Nov 11, 2025SellNVAXRuxandra Draghia-AkliSection 166,048$7.40$1.6B-21.30%+51.94%$44.8K-14.14%Trim
Mar 7, 2025SellNVAXJames Patrick KellyEVP, CFO and Treasurer5,904$8.34$1.6B-21.30%+51.94%$49.2K-6.76%Trim
Mar 7, 2025SellNVAXJohn TrizzinoPresident and COO13,954$8.34$1.6B-21.30%+51.94%$116.4K-12.58%Trim
Mar 1, 2025SellNVAXMark J CaseyEVP, Chief Legal Officer1,214$8.33$1.6B-21.30%+51.94%$10.1K-2.95%Trim
Mar 1, 2025SellNVAXElaine O'HaraEVP, Chief Strategy Officer16,344$8.33$1.6B-21.30%+51.94%$136.1K-6.76%Trim
Mar 1, 2025SellNVAXJohn TrizzinoPresident and COO23,185$8.33$1.6B-21.30%+51.94%$193.1K-13.46%Trim
Mar 1, 2025SellNVAXJames Patrick KellyEVP, CFO and Treasurer28,337$8.33$1.6B-21.30%+51.94%$236.0K-13.58%Trim
Mar 1, 2025SellNVAXJohn C JacobsPresident and CEO38,451$8.33$1.6B-21.30%+51.94%$320.3K-11.25%Trim
Jan 23, 2025SellNVAXJohn C JacobsPresident and CEO38,873$9.55$1.6B-21.30%+51.94%$371.2K-18.17%Trim
Dec 31, 2024SellNVAXJames Patrick KellyEVP, CFO and Treasurer16,906$8.04$1.6B-21.30%+51.94%$135.9K-34.15%Trim
Dec 11, 2024SellNVAXMark J CaseyEVP, Chief Legal Officer12,713$8.82$1.6B-21.30%+51.94%$112.1K-10.11%Trim
Aug 19, 2024SellNVAXJohn TrizzinoEVP, CCO and CBO317$13.90$1.6B-21.30%+51.94%$4.4K-1.11%Trim
Aug 16, 2024BuyNVAXJames Patrick KellyEVP, CFO and Treasurer3,590$12.96$1.6B-21.30%+51.94%$46.5K+3.95%Trim
Jun 17, 2024SellNVAXFilip DubovskyPresident, R&D27,808$10.32$1.6B-21.30%+51.94%$287.1K+0.00%Trim
May 14, 2024SellNVAXFilip DubovskyPresident, R&D66,964$11.87$1.6B-21.30%+51.94%$794.6K-13.79%Trim
Mar 10, 2024SellNVAXJohn TrizzinoPresident and COO2,226$5.45$1.6B-21.30%+51.94%$12.1K-6.40%Trim
Mar 10, 2024SellNVAXJames Patrick KellyEVP, CFO and Treasurer2,226$5.45$1.6B-21.30%+51.94%$12.1K-11.06%Trim
Mar 10, 2024SellNVAXFilip DubovskyPresident, R&D2,597$5.45$1.6B-21.30%+51.94%$14.2K-3.48%Trim
Mar 7, 2024SellNVAXJames Patrick KellyEVP, CFO and Treasurer5,905$5.61$1.6B-21.30%+51.94%$33.1K-7.74%Trim
Mar 7, 2024SellNVAXFilip DubovskyPresident, R&D9,392$5.61$1.6B-21.30%+51.94%$52.7K-12.83%Trim
Mar 7, 2024SellNVAXJohn TrizzinoEVP, CCO and CBO13,955$5.61$1.6B-21.30%+51.94%$78.3K-35.29%Trim
Mar 1, 2024BuyNVAXElaine O'HaraEVP, Chief Strategy Officer24,975$5.39$1.6B-21.30%+51.94%$134.6K+24.19%Trim
Jan 23, 2024SellNVAXJohn C JacobsPresident and CEO40,093$4.26$1.6B-21.30%+51.94%$170.8K-16.06%Trim
Dec 14, 2023SellNVAXJohn A Iii HerrmannEVP, Chief Legal Officer700$5.69$1.6B-21.30%+51.94%$4.0K-5.02%Trim
Dec 14, 2023SellNVAXJohn TrizzinoEVP, CCO and CBO773$5.69$1.6B-21.30%+51.94%$4.4K-6.76%Trim
Dec 14, 2023BuyNVAXFilip DubovskyPresident, R&D4,201$5.69$1.6B-21.30%+51.94%$23.9K+1.36%Trim
Nov 5, 2023BuyNVAXFilip DubovskyPresident, R&D2,077$7.06$1.6B-21.30%+51.94%$14.7K+0.69%Trim
Sep 16, 2023BuyNVAXFilip DubovskyPresident, R&D18,752$7.71$1.6B-21.30%+51.94%$144.6K+6.36%Trim